secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2021-11-22T23:59:59+00:00
Accession:  0001193125-21-336078
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Therapeutics appoints Dr. June Lee to board; Dr. JeenJoo Kang resigns
----------------------------------------------------------------------------

- Dr. June Lee appointed as Class III director, term expiring at 2024 annual meeting.
- Dr. Lee receives annual cash retainer of $35,000 and stock option grant with ~$320,000 fair value.
- Dr. Lee most recently CEO of Esker Therapeutics; previously EVP at MyoKardia advancing cardiomyopathies.
- Dr. JeenJoo Kang resigned voluntarily, not due to any disagreement, to focus on CEO role at Appia Bio.
- Company highlights transition to clinical-stage and Dr. Lee's relevant development experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000119312521336078/0001193125-21-336078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000119312521336078/d255712d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-336078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer